A New Unexplained Top Secret Inside PD0325901 Totally Exposed

Analyses of time-to-event outcomes are presented as Kaplan�CMeier graphs with trials compared using Cox regression; dichotomous endpoints are compared using logistic http://www.selleckchem.com/products/PD-0325901.html regression. Multivariate analyses using forward selection are used to investigate the effect of the trial adjusted for baseline covariates, which include age, sex, performance status, secondary disease, cytogenetics and log[white blood cell count] (log [WBC]), and interactions with trial explored using the likelihood ratio test. Follow up is complete until 1 January 2011. By convention, odds (OR) or hazard ratios (HR) >1 indicated worse outcomes in AML16. All p-values are two sided, with significance set at P? http://www.selleckchem.com/products/3-methyladenine.html to be older (P? http://www.selleck.cn/products/Cisplatin.html 1��14 (0��55�C2��33) P?=?0��7 Unadjusted OR 1��46 (0��64�C3��3) P?=?0��4 Adjusted OR 1��48 (0��44�C4��98) P?=?0��5 The overall remission rate across the trials was 71% (Table?1). While the outcome estimates were worse in AML16 than AML15, there were no statistically significant differences in remission rates, induction death or resistant disease rates between trials, either in univariate or multivariate analyses. Overall survival was significantly worse in AML16 than AML15 (median survival 16?months vs. 27?months; 3-year overall survival 20% vs. 42%, HR 1��62, 95% CI 1��20�C2��17; P?=?0��001; Fig?1A). In multivariate analyses adjusted for age, performance status, cytogenetic profile and log [WBC], AML16 retained its poor prognostic value (HR 1��55 (95% CI 1��09, 2��22), P?=?0��02, Fig?1B). A similar difference was seen for relapse-free survival (median 12?months vs. 21?months; unadjusted HR 1��87 (95% CI 1��33�C2��62), P?